The company is a large ophthalmology medical chain group and a company listed on the Shenzhen Stock Exchange GEM. As of 2023, the Group has managed more than 100 ophthalmology hospitals and optometry centers across the country. As a pioneer in the general ophthalmology diagnosis and treatment service system, Huaxia Ophthalmology's business scope covers the entire life cycle. It has established an ophthalmology general diagnosis and treatment service system covering eight major ophthalmology subspecialty departments and ophthalmology, ocular surface, glaucoma, orbital and eye tumors, and eye trauma. The company's main business is ophthalmic medical services, providing ophthalmic medical services such as diagnosis and treatment of various ophthalmic diseases to patients with ophthalmic diseases. Corporate honors: National Key Clinical Specialties, Academician Workstations, Postdoctoral Workstations, etc. The company has been awarded many honors such as “2023 ESG Brand Influential Enterprise”, “2023 ESG Pioneer Enterprise Award”, and “Social Responsibility Pioneer Enterprise Award”.
No Data
No Data